146 results on '"Lapi SE"'
Search Results
2. Production and separation of 7 Be for use in an ion source.
- Author
-
Satija S, Domnanich KA, Sumithrarachchi C, Liu Y, Cingoranelli SJ, Saini S, Chaple I, Lapi SE, and Severin GW
- Abstract
Beryllium-7 (
7 Be) was created by proton irradiation of natural (nat B) and enriched (10 B) boron targets. The targets were dissolved in nitric acid, and the7 Be was separated from the bulk boron target material by cation-exchange chromatography. An average recovery of (99.4 ± 3.7)% was obtained for 6 separations. The purified7 Be sample was placed into a batch-mode ion source to create a7 Be beam that was delivered at an average rate of 5 × 105 pps to end users at the National Superconducting Cyclotron Laboratory., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
3. Development of 52 Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.
- Author
-
Omweri JM, Saini S, Houson HA, Tekin V, Pyles JM, Parker CC, and Lapi SE
- Abstract
Purpose: Due to their long circulation time in the blood, monoclonal antibodies (mAbs) such as trastuzumab, are usually radiolabeled with long-lived positron emitters for the development of agents for Positron Emission Tomography (PET) imaging. Manganese-52 (
52 Mn, t1/2 = 5.6 d, β+ = 29.6%, E(βave ) = 242 keV) is suitable for imaging at longer time points providing a complementary technique to Zirconium-89 (89 Zr, t1/2 = 3.3 d, β+ = 22.7%, E(βave ) = 396 keV)) because of its long half-life and low positron energy. To exploit these properties, we aimed to investigate suitable bifunctional chelators that could be readily conjugated to antibodies and labeled with52 Mn under mild conditions using trastuzumab as a proof-of-concept., Procedures: Trastuzumab was incubated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), 1-Oxa-4,7,10-tetraazacyclododecane-5-S-(4-isothiocyantobenzyl)-4,7,10-triacetic acid (p-SCN-Bn-Oxo-DO3A), and 3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-1(15),11,13-triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid (p-SCN-Bn-PCTA) at a tenfold molar excess. The immunoconjugates were purified, combined with [52 Mn]MnCl2 at different ratios, and the labeling efficiency was assessed by iTLC. The immunoreactive fraction of the radiocomplex was determined through a Lindmo assay. Cell studies were conducted in HER2 + (BT474) and HER2- (MDA-MB-468) cell lines followed by in vivo studies., Results: Trastuzumab-Oxo-DO3A was labeled within 30 min at 37 °C with a radiochemical yield (RCY) of 90 ± 1.5% and with the highest specific activity of the chelators investigated of 16.64 MBq/nmol. The labeled compound was purified with a resulting radiochemical purity of > 98% and retained a 67 ± 1.2% immunoreactivity. DOTA and PCTA immunoconjugates resulted in < 50 ± 2.5% (RCY) with similar specific activity. Mouse serum stability studies of [52 Mn]Mn-Oxo-DO3A-trastuzumab showed 95% intact complex for over 5 days. Cell uptake studies showed higher uptake in HER2 + (12.51 ± 0.83% /mg) cells compared to HER2- (0.85 ± 0.10%/mg) cells. PET images of mice bearing BT474 tumors showed high tumor uptake that was consistent with the biodistribution (42.02 ± 2.16%ID/g, 14 d) compared to MDA-MB-468 tumors (2.20 ± 0.80%ID/g, 14 d). Additionally, both models exhibited low bone uptake of < 1% ID/g., Conclusion: The bifunctional chelator p-SCN-Bn-Oxo-DO3A is promising for the development of52 Mn radiopharmaceuticals as it was easily conjugated, radiolabeled at mild conditions, and illustrated stability for a prolonged duration both in vitro and in vivo. High-quality PET/CT images of [52 Mn]Mn-Oxo-DO3A-trastuzumab were obtained 14 d post-injection. This study illustrates the potential of [52 Mn]Mn-Oxo-DO3A for the evaluation of antibodies using PET imaging., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
4. PET imaging of [52 Mn]Mn-DOTATATE and [52 Mn]Mn-DOTA-JR11.
- Author
-
Omweri JM, Houson HA, Lynch SE, Tekin V, Sorace AG, and Lapi SE
- Abstract
Manganese-52 is gaining interest as an isotope for PET imaging due to its desirable decay and chemical properties for radiopharmaceutical development. Somatostatin receptor 2 (SSTR2) is significantly overexpressed by neuroendocrine tumors (NETs) and is an important target for nuclear imaging and therapy. As an agonist, [
68 Ga]Ga-DOTATATE has demonstrated significant internalization upon interaction with receptor ligands, whereas [68 Ga]Ga-DOTA-JR11(as an antagonist) exhibits limited internalization but better pharmacokinetics and increased tumor uptake. The goal of this study was to label both DOTATATE and DOTA-JR11 peptides with52 Mn in high radiochemical yields (RCY) and sufficient specific activity. A comparison of these two compounds was performed in in vitro and in vivo studies in animals with somatostatin receptor-positive xenografts to characterize differences in cell, tumor, and tissue uptake. Radiolabeling of DOTATATE and DOTA-JR11 was carried out by combining varying concentrations of the peptides with [52 Mn]MnCl2 . In vitro stability of the radiotracers was determined in mouse serum. In vitro cell uptake and internalization assays were performed in SSTR2 + AR42J cells and negative controls. In vivo biodistribution and longitudinal PET imaging was evaluated in mice bearing AR42J tumors. Both [52 Mn]Mn-DOTATATE and [52 Mn]Mn-DOTA-JR11showed affinity for SSTR2 in AR42J cells. However, the uptake of [52 Mn]Mn-DOTATATE was higher (11.95 ± 0.71%/ mg) compared to [52 Mn]Mn-DOTA-JR11 (7.31 ± 0.38%/ mg) after 2 h incubation. After 4 h incubation, 53.13 ± 1.83% of the total activity of [52 Mn]Mn-DOTATATE was internalized, whereas only 20.85 ± 0.59% of the total activity of [52 Mn]Mn-DOTA-JR11 was internalized. The PET images revealed similar biodistribution results, with [52 Mn]Mn-DOTATATE showing a significant tumor uptake of 11.16 ± 2.97% ID/g, while [52 Mn]Mn-DOTA-JR11 exhibited a lower tumor uptake of 2.11 ± 0.30% ID/g 4 h post-injection. The synthesis of both radiotracers was accomplished with high RCY and purity. The cell uptake and internalization of [52 Mn]Mn-DOTATATE showed higher levels compared to [52 Mn]Mn-DOTA-JR11. PET images of the radiotracers in AR42J tumor bearing mice demonstrated similar biodistribution in all organs except the tumor, with [52 Mn]Mn-DOTATATE showing higher tumor uptake compared to [52 Mn]Mn-DOTA-JR11. The variations in properties of these tracers could be used to guide further imaging and treatment studies., Competing Interests: Declaration of competing interest The authors declare no known competing interests. Additional Declarations: No competing interests reported.- Published
- 2024
- Full Text
- View/download PDF
5. PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [ 89 Zr]Zr-TR1402.
- Author
-
Gimblet GR, Houson HA, Whitt J, Reddy P, Copland JA, Kenderian SS, Szkudlinski MW, Jaskula-Sztul R, and Lapi SE
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Female, Radiopharmaceuticals pharmacokinetics, Radiopharmaceuticals chemistry, Tissue Distribution, Male, Radioisotopes chemistry, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms metabolism, Thyroid Neoplasms pathology, Zirconium chemistry, Positron-Emission Tomography methods, Receptors, Thyrotropin metabolism, Receptors, Thyrotropin genetics, Mice, Nude
- Abstract
Thyroid cancer is the most common endocrine cancer, with differentiated thyroid cancers (DTCs) accounting for 95% of diagnoses. While most DTC patients are diagnosed and treated with radioiodine (RAI), up to 20% of DTC patients become RAI refractory (RAI-R). RAI-R patients have significantly reduced survival rates compared to patients who remain RAI-avid. This study explores [
89 Zr]Zr-TR1402 as a thyroid-stimulating hormone receptor (TSHR)-targeted PET radiopharmaceutical for DTC. [89 Zr]Zr-TR1402 was synthesized with a molar activity of 25.9 MBq/nmol by conjugating recombinant human TSH (rhTSH) analogue TR1402 to chelator p-SCN-Bn-deferoxamine (DFO) in a molar ratio of 3:1 (DFO/TR1402) and radiolabeling with89 Zr ( t1/2 = 78.4 h, β+ = 22.7%). As TSHR is absent in commonly available DTC-derived cell lines, TSHR was reintroduced via stable transduction by delivering a lentivirus containing the full-length coding region of the human TSHR gene. Receptor-mediated uptake of [89 Zr]Zr-TR1402 was evaluated in vitro in stably transduced TSHR+ and wild-type TSHR- DTC cell lines. In vivo PET imaging was performed on Days 1-3 postinjection in male and female athymic nude mice bearing TSHR+ and TSHR- xenografts, along with ex vivo biodistribution on Day 3 postinjection. In vitro uptake of 1 nM [89 Zr]Zr-TR1402 was significantly higher in TSHR+ THJ529T ( P < 0.0001) and FTC133 ( P < 0.01) cells than in TSHR- THJ529T and FTC133 cells. This uptake was shown to be specific in both TSHR+ THJ529T ( P < 0.0001) and TSHR+ FTC133 ( P < 0.0001) cells by blocking uptake with 250 nm DFO-TR1402. In vivo PET imaging showed accumulation of [89 Zr]Zr-TR1402 in TSHR+ tumors, which was the highest on Day 1. In the male FTC133 xenograft model, ex vivo biodistribution confirmed a significant difference ( P < 0.001) in uptake between FTC133+ (1.3 ± 0.1%ID/g) and FTC133- (0.8 ± 0.1%ID/g) tumors. A significant difference ( P < 0.05) in uptake was also seen in the male THJ529T xenograft model between THJ529T+ (1.8 ± 0.6%ID/g) and THJ529T- (0.8 ± 0.4%ID/g) tumors. The in vitro and in vivo accumulation of [89 Zr]Zr-TR1402 in TSHR-expressing DTC cell lines support the continued preclinical optimization of this approach.- Published
- 2024
- Full Text
- View/download PDF
6. Improving the In Vivo Stability of [ 52 Mn]Mn(II) Complexes with 18-Membered Macrocyclic Chelators for PET Imaging.
- Author
-
Harriswangler C, Omweri JM, Saini S, Valencia L, Esteban-Gómez D, Ranga M, Guidolin N, Baranyai Z, Lapi SE, and Platas-Iglesias C
- Subjects
- Animals, Mice, Crystallography, X-Ray, Coordination Complexes chemistry, Coordination Complexes chemical synthesis, Coordination Complexes pharmacokinetics, Tissue Distribution, Models, Molecular, Radiopharmaceuticals chemistry, Radiopharmaceuticals chemical synthesis, Radiopharmaceuticals pharmacokinetics, Drug Stability, Positron-Emission Tomography methods, Macrocyclic Compounds chemistry, Macrocyclic Compounds chemical synthesis, Macrocyclic Compounds pharmacokinetics, Manganese chemistry, Chelating Agents chemistry, Chelating Agents chemical synthesis
- Abstract
We report the [
nat Mn/52 Mn]Mn(II) complexes of the macrocyclic chelators PYAN [3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane] and CHXPYAN [(41 R ,42 R ,101 R ,102 R )-3,5,9,11-tetraaza-1,7(2,6)-dipyridina-4,10(1,2)-dicyclohexanacyclododecaphane]. The X-ray crystal structures of Mn-PYAN and Mn-CHXPYAN evidence distorted octahedral geometries through coordination of the nitrogen atoms of the macrocycles. Cyclic voltammetry studies evidence reversible processes due to the Mn(II)/Mn(III) pair, indicating that the complexes are resistant to oxidation. CHXPYAN forms a more thermodynamically stable and kinetically inert Mn(II) complex than PYAN. Radiochemical studies with the radioactive isotope manganese-52 (52 Mn, t1/2 = 5.6 days) evidenced better radiochemical yields for CHXPYAN than for PYAN. Both [52 Mn]Mn(II) complexes remained stable in mouse and human serum, so in vivo stability studies were carried out. Positron emission tomography/computed tomography scans and biodistribution assays indicated that [52 Mn]Mn-PYAN has a distribution pattern similar to that of [52 Mn]MnCl2 , showing persistent radioactivity accumulation in the kidneys. Conversely, [52 Mn]Mn-CHXPYAN remained stable in vivo, clearing quickly from the liver and kidneys.- Published
- 2024
- Full Text
- View/download PDF
7. [ 18 F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response.
- Author
-
McNeal KC, Reeves KM, Song PN, Lapi SE, Sorace AG, and Larimer BM
- Subjects
- Animals, Mice, Cell Line, Tumor, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms therapy, Female, Tumor Microenvironment, Positron-Emission Tomography methods, Misonidazole analogs & derivatives, Tumor Hypoxia drug effects, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology
- Abstract
Context: Hypoxia within the tumor microenvironment is a critical factor influencing the efficacy of immunotherapy, including immune checkpoint inhibition. Insufficient oxygen supply, characteristic of hypoxia, has been recognized as a central determinant in the progression of various cancers. The reemergence of evofosfamide, a hypoxia-activated prodrug, as a potential treatment strategy has sparked interest in addressing the role of hypoxia in immunotherapy response. This investigation sought to understand the kinetics and heterogeneity of tumor hypoxia and their implications in affecting responses to immunotherapeutic interventions with and without evofosfamide., Purpose: This study aimed to investigate the influence of hypoxia on immune checkpoint inhibition, evofosfamide monotherapy, and their combination on colorectal cancer (CRC). Employing positron emission tomography (PET) imaging, we developed novel analytical methods to quantify and characterize tumor hypoxia severity and distribution., Procedures: Murine CRC models were longitudinally imaged with [
18 F]-fluoromisonidazole (FMISO)-PET to quantify tumor hypoxia during checkpoint blockade (anti-CTLA-4 + and anti-PD1 +/- evofosfamide). Metrics including maximum tumor [18 F]FMISO uptake (FMISOmax) and mean tumor [18 F]FMISO uptake (FMISOmean) were quantified and compared with normal muscle tissue (average muscle FMISO uptake (mAvg) and muscle standard deviation (mSD)). Histogram distributions were used to evaluate heterogeneity of tumor hypoxia., Findings: Severe hypoxia significantly impeded immunotherapy effectiveness consistent with an immunosuppressive microenvironment. Hypoxia-specific PET imaging revealed a striking degree of spatial heterogeneity in tumor hypoxia, with some regions exhibiting significantly more severe hypoxia than others. The study identified FMISOmax as a robust predictor of immunotherapy response, emphasizing the impact of localized severe hypoxia on tumor volume control during therapy. Interestingly, evofosfamide did not directly reduce hypoxia but markedly improved the response to immunotherapy, uncovering an alternative mechanism for its efficacy., Conclusions: These results enhance our comprehension of the interplay between hypoxia and immune checkpoint inhibition within the tumor microenvironment, offering crucial insights for the development of personalized cancer treatment strategies. Non-invasive hypoxia quantification through molecular imaging evaluating hypoxia severity may be an effective tool in guiding treatment planning, predicting therapy response, and ultimately improving patient outcomes across diverse cancer types and tumor microenvironments. It sets the stage for the translation of these findings into clinical practice, facilitating the optimization of immunotherapy regimens by addressing tumor hypoxia and thereby enhancing the efficacy of cancer treatments., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Benjamin Larimer reports financial support was provided by National Institutes of Health. Anna Sorace reports financial support was provided by National Institutes of Health. Benjamin Larimer reports a relationship with National Institutes of Health that includes: funding grants. Anna Sorace reports a relationship with National Institutes of Health that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
8. Cross section measurements for the production of 49,51 Cr and 47 Sc from proton irradiation of natural vanadium up to 24 MeV.
- Author
-
Cingoranelli SJ, Burnett L, Putnam E, and Lapi SE
- Abstract
Scandium-47 is a promising radionuclide for targeted radiotherapy and is also an elementally matched therapeutic partner to
43 Sc and44 Sc, which are suitable for Positron Emission Tomography. The predominantly reported routes for the production of47 Sc employ expensive enriched titanium or calcium targets to achieve high radionuclidic purity. This study reports measurements of the excitation function of thenat V(p,x)47 Sc reaction at proton energies of 18-24 MeV to optimize bombardment parameters for the production of47 Sc using this promising approach. The cross-sections reported here demonstrate that irradiation of vanadium targets can produce >99% radionuclidically pure47 Sc with a proton energy of 24 MeV, albeit at modest yields., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
9. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models.
- Author
-
Lu Y, Houson HA, Gallegos CA, Mascioni A, Jia F, Aivazian A, Song PN, Lynch SE, Napier TS, Mansur A, Larimer BM, Lapi SE, Hanker AB, and Sorace AG
- Subjects
- Animals, Female, Mice, Humans, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Cell Line, Tumor, Zirconium, Radiopharmaceuticals, Radioisotopes, Tumor Microenvironment immunology, CD8-Positive T-Lymphocytes immunology, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, Positron-Emission Tomography methods, Breast Neoplasms diagnostic imaging, Breast Neoplasms immunology, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms therapy, Disease Models, Animal
- Abstract
Background: Immune-positron emission tomography (PET) imaging with tracers that target CD8 and granzyme B has shown promise in predicting the therapeutic response following immune checkpoint blockade (ICB) in immunologically "hot" tumors. However, immune dynamics in the low T-cell infiltrating "cold" tumor immune microenvironment during ICB remain poorly understood. This study uses molecular imaging to evaluate changes in CD4 + T cells and CD8 + T cells during ICB in breast cancer models and examines biomarkers of response., Methods: [
89 Zr]Zr-DFO-CD4 and [89 Zr]Zr-DFO-CD8 radiotracers were used to quantify changes in intratumoral and splenic CD4 T cells and CD8 T cells in response to ICB treatment in 4T1 and MMTV-HER2 mouse models, which represent immunologically "cold" tumors. A correlation between PET quantification metrics and long-term anti-tumor response was observed. Further biological validation was obtained by autoradiography and immunofluorescence., Results: Following ICB treatment, an increase in the CD8-specific PET signal was observed within 6 days, and an increase in the CD4-specific PET signal was observed within 2 days in tumors that eventually responded to immunotherapy, while no significant differences in CD4 or CD8 were found at the baseline of treatment that differentiated responders from nonresponders. Furthermore, mice whose tumors responded to ICB had a lower CD8 PET signal in the spleen and a higher CD4 PET signal in the spleen compared to non-responders. Intratumoral spatial heterogeneity of the CD8 and CD4-specific PET signals was lower in responders compared to non-responders. Finally, PET imaging, autoradiography, and immunofluorescence signals were correlated when comparing in vivo imaging to ex vivo validations., Conclusions: CD4- and CD8-specific immuno-PET imaging can be used to characterize the in vivo distribution of CD4 + and CD8 + T cells in response to immune checkpoint blockade. Imaging metrics that describe the overall levels and distribution of CD8 + T cells and CD4 + T cells can provide insight into immunological alterations, predict biomarkers of response to immunotherapy, and guide clinical decision-making in those tumors where the kinetics of the response differ., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
10. Production and regulatory issues for theranostics.
- Author
-
Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A, Korde A, Knoll P, Ayati N, Lewis JS, Lapi SE, Delgado Bolton RC, Kunikowska J, Estrada Lobato E, Urbain JL, Holmberg O, Abdel-Wahab M, and Scott AM
- Subjects
- Humans, Neoplasms therapy, Precision Medicine, Radiopharmaceuticals therapeutic use, Theranostic Nanomedicine
- Abstract
Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer., Competing Interests: Declaration of interests RZ reports direct relations with Global Morpho Pharma, Posifit–Nancyclotep, LemerPax, MEDraysintell, Chrysalium Consulting, and Telix Pharma. NA reports having received a travel grant from the Australian and New Zealand Society of Nuclear Medicine. JSL reports research support from Clarity Pharmaceuticals and AVID Radiopharmaceuticals; has acted as an adviser of Boxer, Clarity Pharmaceuticals, Curie Therapeutics, Earli, Evergreen Theragnostics, NexTech Invest, Telix Pharmaceuticals, Suba Therapeutics, inhibrx, Precirix, Alpha-9 Oncology, and TPG Capital; is a co-inventor on technologies licensed to Diaprost, Elucida Oncology, Theragnostics, CheMatech, and Samus Therapeutics; is the co-founder of pHLIP; holds equity in Summit Biomedical Imaging, Telix Pharmaceuticals, and Evergreen Theragnostics; and is supported by National Institutes of Health R35 CA232130. SEL reports research support from Navidea Biopharmaceuticals, Fusion Pharmaceuticals, Cytosite Biopharma, Viewpoint Molecular Targeting, and Genzyme Corporation; has acted as an adviser for NorthStar Medical Radioisotopes and Trevarx biomedical; and is supported by the US Department of Energy as part of the DOE University Isotope Network under grant DESC0021269. JK reports participation on a data safety monitoring board and advisory board for Novartis (personal fees), and an unrestricted grant from Janssen. AMS reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; research funding from Medimmune, AVID Radiopharmaceuticals, Adalta, Antengene, Humanigen, Telix Pharmaceuticals, and Theramyc; is a co-inventor on technologies licensed to Humanigen, AbbVie and Life Science Pharmaceuticals; participates on the advisory boards of Imagion and ImmunOs; and is supported by an Australian National Health and Medical Research Council grant number 1177837. CSC is supported by the US Department of Energy under grants Lab 20-2301, DE-FOA-0003063, and DE-FOA-0002532. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
11. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
- Author
-
Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, and Lewis JS
- Subjects
- Humans, Medical Oncology, Artificial Intelligence, Radiopharmaceuticals therapeutic use, Neoplasms therapy, Neoplasms radiotherapy
- Abstract
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer., Competing Interests: Declaration of interests SEL reports research support from Navidea Biopharmaceuticals, Fusion Pharmaceuticals, Cytosite Biopharma, Viewpoint Molecular Targeting, and Genzyme Corporation; has acted as an advisor for NorthStar Medical Radioisotopes and Trevarx Biomedical; and is supported by the Department of Energy as part of the Department of Energy University Isotope Network under grant DESC0021269. PJHS reports research support from Bristol Myers Squibb, Telix Pharmaceuticals, and Radionetics Oncology; has acted as an adviser to Synfast Consulting and Telix Pharmaceuticals; holds equity in Bristol Myers Squibb, Telix Pharmaceuticals, and Novartis; and is supported by National Institutes of Health R01 EB021155. AMS reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; research funding from Medimmune, AVID Radiopharmaceuticals, Adalta, Antengene, Humanigen, Telix Pharmaceuticals, and Theramyc; is on the advisory boards of Imagion and ImmunOs; and is supported by Australian National Health and Medical Research Council grant number 1177837. ADW reports his role as the Editor in Chief of Nuclear Medicine and Biology. BMZ holds equity in Summit Biomedical Imaging. RPB is an advisor to 3B Pharmaceuticals (Berlin, Germany), ITM, Full Life Technologies, Sinotau, Jiangsu Huayi Technology, and Telix Pharmaceuticals. APK reports clinical trial funding from Novartis, Bayer, POINT, and Merck; and unpaid consulting for Novartis. JK reports an unrestricted grant from Janssen, and consulting fees from Telix and Novartis. JSL reports research support from Clarity Pharmaceuticals and Avid Radiopharmaceuticals; has acted as an adviser of Alpha-9 Theranostics, Clarity Pharmaceuticals, Earli, Evergreen Theragnostics, Inhibrix, Precirix, and Telix Pharmaceuticals; is a co-inventor on technologies licensed to Diaprost, Elucida Oncology, Theragnostics, CheMatech, Clarity Pharmaceuticals, and Samus Therapeutics; is the co-founder of pHLIP; holds equity in Summit Biomedical Imaging, Telix Pharmaceuticals, Clarity Pharmaceuticals, and Evergreen Theragnostics; and is supported by National Institutes of Health R35 CA232130. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
12. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
- Author
-
Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, Giammarile F, Piaez D, Jalilian A, Knoll P, Korde A, Vichare S, Ayati N, Lee ST, Lyashchenko SK, Zhang J, Urbain JL, and Lewis JS
- Subjects
- Humans, Neoplasms radiotherapy, Neoplasms therapy, Health Workforce trends, Radiopharmaceuticals therapeutic use, Radiopharmaceuticals supply & distribution, Nuclear Medicine education, Nuclear Medicine trends, Medical Oncology
- Abstract
Although the promise of radionuclides for the diagnosis and treatment of disease was recognised soon after the discovery of radioactivity in the late 19th century, the systematic use of radionuclides in medicine only gradually increased over the subsequent hundred years. The past two decades, however, has seen a remarkable surge in the clinical application of diagnostic and therapeutic radiopharmaceuticals, particularly in oncology. This development is an exciting time for the use of theranostics in oncology, but the rapid growth of this area of nuclear medicine has created challenges as well. In particular, the infrastructure for the manufacturing and distribution of radiopharmaceuticals remains in development, and regulatory bodies are still optimising guidelines for this new class of drug. One issue of paramount importance for achieving equitable access to theranostics is building a sufficiently trained workforce in high-income, middle-income, and low-income countries. Here, we discuss the key challenges and opportunities that face the field as it seeks to build its workforce for the 21st century., Competing Interests: Declaration of interests Outside the submitted work: AMS reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; research funding from Medimmune, AVID Radiopharmaceuticals, Adalta, Antengene, Humanigen, Telix Pharmaceuticals, and Theramyc; and payment for participation in advisory boards of Imagion and Immunos. BMZ reports research funding from Evergreen Theragnostics, equity in Summit Biomedical Imaging, and has licensed technologies to Clarity Pharmaceuticals. SEL reports research support from Navidea Biopharmaceuticals, Fusion Pharmaceuticals, Cytosite Biopharma, Viewpoint Molecular Targeting, and Genzyme Corporation, and has acted as an advisor for NorthStar Medical Radioisotopes and Trevarx biomedical. PJHS reports research support from Bristol Myers Squibb, Telix Pharmaceuticals, and Radionetics Oncology; has acted as an adviser to Synfast Consulting and Telix Pharmaceuticals; and holds equity in Bristol Myers Squibb, Telix Pharmaceuticals, and Novartis. ADW reports their role as Editor-in-Chief of Nuclear Medicine and Biology. JSL reports research support from Clarity Pharmaceuticals and Avid Radiopharmaceuticals; has acted as an adviser of Alpha-9 Theranostics, Clarity Pharmaceuticals, Earli, Evergreen Theragnostics, Inhibrix, Precirix, and Telix Pharmaceuticals; is a co-inventor on technologies licensed to Diaprost, Elucida Oncology, Theragnostics, CheMatech, Clarity Pharmaceuticals, and Samus Therapeutics; is the co-founder of pHLIP; and holds equity in Summit Biomedical Imaging, Telix Pharmaceuticals, Clarity Pharmaceuticals, and Evergreen Theragnostics. AMS is supported by National Health and Medical Research Council grant number 1177837. SEL is supported by the Department of Energy as part of the DOE University Isotope Network, under grant DESC0021269. PJHS is supported by grant R01 EB021155. JSL is supported by National Institutes of Health grant R35 CA232130. MA-W, AJ, AK, PK, SV, STL, SKL, DP, JZ, JLU, and FG report no competing interests. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
13. Customizable Porphyrin Platform Enables Folate Receptor PET Imaging Using Copper-64.
- Author
-
Houson HA, Wu Z, Cao PD, Lindsey JS, and Lapi SE
- Subjects
- Animals, Humans, Mice, Female, Cell Line, Tumor, Porphyrins chemistry, Folate Receptor 1 metabolism, Tissue Distribution, Mice, Nude, Radiopharmaceuticals pharmacokinetics, Radiopharmaceuticals chemistry, Folic Acid chemistry, Xenograft Model Antitumor Assays, Copper Radioisotopes chemistry, Positron-Emission Tomography methods, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms metabolism
- Abstract
Folate receptors including folate receptor α (FRα) are overexpressed in up to 90% of ovarian cancers. Ovarian cancers overexpressing FRα often exhibit high degrees of drug resistance and poor outcomes. A porphyrin chassis has been developed that is readily customizable according to the desired targeting properties. Thus, compound O5 includes a free base porphyrin, two water-solubilizing groups that project above and below the macrocycle plane, and a folate targeting moiety. Compound O5 was synthesized (>95% purity) and exhibited aqueous solubility of at least 0.48 mM (1 mg/mL). Radiolabeling of O5 with
64 Cu in HEPES buffer at 37 °C gave a molar activity of 1000 μCi/μg (88 MBq/nmol). [64 Cu]Cu-O5 was stable in human serum for 24 h. Cell uptake studies showed 535 ± 12% bound/mg [64 Cu]Cu-O5 in FRα-positive IGROV1 cells when incubated at 0.04 nM. Subcellular fractionation showed that most radioactivity was associated with the cytoplasmic (39.4 ± 2.7%) and chromatin-bound nuclear (53.0 ± 4.2%) fractions. In mice bearing IGROV1 xenografts, PET imaging studies showed clear tumor uptake of [64 Cu]Cu-O5 from 1 to 24 h post injection with a low degree of liver uptake. The tumor standardized uptake value at 24 h post injection was 0.34 ± 0.16 versus 0.06 ± 0.07 in the blocking group. In summary, [64 Cu]Cu-O5 was synthesized at high molar activity, was stable in serum, exhibited high binding to FRα-overexpressing cells with high nuclear translocation, and gave uptake that was clearly visible in mouse tumor xenografts.- Published
- 2024
- Full Text
- View/download PDF
14. The future of the radiopharmaceutical sciences.
- Author
-
Lapi SE and Scott PJH
- Subjects
- Humans, Radiopharmaceuticals
- Abstract
Competing Interests: Declaration of competing interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
15. Titanium-45 ( 45 Ti) Radiochemistry and Applications in Molecular Imaging.
- Author
-
Saini S and Lapi SE
- Abstract
Molecular imaging is an important part of modern medicine which enables the non-invasive identification and characterization of diseases. With the advancement of radiochemistry and scanner technology, nuclear medicine is providing insight into efficient treatment options for individual patients. Titanium-45 (
45 Ti) is a lesser-explored radionuclide that is garnering increasing interest for the development of positron emission tomography (PET) radiopharmaceuticals. This review discusses aspects of this radionuclide including production, purification, radiochemistry development, and molecular imaging studies.- Published
- 2024
- Full Text
- View/download PDF
16. Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.
- Author
-
Song PN, Lynch SE, DeMellier CT, Mansur A, Gallegos CA, Wright BD, Hartman YE, Minton LE, Lapi SE, Warram JM, and Sorace AG
- Subjects
- Humans, Cetuximab pharmacology, Cetuximab therapeutic use, Squamous Cell Carcinoma of Head and Neck drug therapy, Trastuzumab pharmacology, Trastuzumab therapeutic use, Cell Line, Tumor, Tumor Microenvironment, ErbB Receptors, Head and Neck Neoplasms drug therapy
- Abstract
Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and hypoxia are associated with radioresistance. The goal of this study is to study the synergy of anti-HER2, trastuzumab, and anti-EGFR, cetuximab, and characterize the tumor microenvironment components that may lead to increased radiation sensitivity with dual anti-HER2/EGFR therapy in head and neck squamous cell carcinoma (HNSCC). Positron emission tomography (PET) imaging ([
89 Zr]-panitumumab and [89 Zr]-pertuzumab) was used to characterize EGFR and HER2 in HNSCC cell line tumors. HNSCC cells were treated with trastuzumab, cetuximab, or combination followed by radiation to assess for viability and radiosensitivity (colony forming assay, immunofluorescence, and flow cytometry). In vivo, [18 F]-FMISO-PET imaging was used to quantify changes in oxygenation during treatment. Bliss Test of Synergy was used to identify combination treatment synergy. Quantifying EGFR and HER2 receptor expression revealed a 50% increase in heterogeneity of HER2 relative to EGFR. In vitro, dual trastuzumab-cetuximab therapy shows significant decreases in DNA damage response and increased response to radiation therapy (p < 0.05). In vivo, tumors treated with dual anti-HER2/EGFR demonstrated decreased tumor hypoxia, when compared to single agent therapies. Dual trastuzumab-cetuximab demonstrates synergy and can affect tumor oxygenation in HNSCC. Combination trastuzumab-cetuximab modulates the tumor microenvironment through reductions in tumor hypoxia and induces sustained treatment synergy., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
17. Radiochemistry and In Vivo Imaging of [ 45 Ti]Ti-THP-PSMA.
- Author
-
Saini S, Mullen GED, Blower PJ, and Lapi SE
- Subjects
- Male, Humans, Animals, Mice, Radiopharmaceuticals, Radiochemistry, Tissue Distribution, Titanium, Glutamate Carboxypeptidase II metabolism, Antigens, Surface metabolism, Positron-Emission Tomography, Radioisotopes, Chelating Agents, Cell Line, Tumor, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms metabolism
- Abstract
Titanium-45 (
45 Ti) is a radionuclide with excellent physical characteristics for use in positron emission tomography (PET) imaging, including a moderate half-life (3.08 h), decay by positron emission (85%), and a low mean positron energy of 0.439 MeV. However, challenges associated with titanium chemistry have led to the underdevelopment of this radionuclide for incorporation into radiopharmaceuticals. Expanding on our recent studies, which showed promising results for the complexation of45 Ti with the tris hydroxypyridinone (THPMe ) chelator, the current work aimed to optimize the chemistry and imaging attributes of [45 Ti]Ti-THP-PSMA as a new PET radiopharmaceutical. Methods . Radiolabeling of THP-PSMA was optimized with [45 Ti]Ti-citrate at varying pHs and masses of the precursor. The stability of the radiolabeled complex was assessed in mouse serum for up to 6 h. The affinity of [45 Ti]Ti-THP-PSMA for prostate-specific membrane antigen (PSMA) was assessed using LNCaP (PSMA +) and PC3 (PSMA -) cell lines. In vivo imaging and biodistribution analysis were performed in tumor-bearing xenograft mouse models to confirm the specificity of the tumor uptake. Results . > 95% of radiolabeling was achieved with a high specific activity of 5.6 MBq/nmol under mild conditions. In vitro cell binding studies showed significant binding of the radiolabeled complex with the PSMA-expressing LNCaP cell line (11.9 ± 1.5%/mg protein-bound activity) compared to that with the nonexpressing PC3 cells (1.9 ± 0.4%/mg protein-bound activity). In vivo imaging and biodistribution studies confirmed specific uptake in LNCaP tumors (1.6 ± 0.27% ID/g) compared to that in PC3 tumors (0.39 ± 0.2% ID/g). Conclusion. This study showed a simple one-step radiolabeling method for45 Ti with THP-PSMA under mild conditions (pH 8 and 37 °C). In vitro cell studies showed promise, but in vivo tumor xenograft studies indicated low tumor uptake. Overall, this study shows the need for more chelators for45 Ti for the development of a PET radiopharmaceutical for cancer imaging.- Published
- 2024
- Full Text
- View/download PDF
18. Chelation chemistry of manganese-52 for PET imaging applications.
- Author
-
Omweri JM, Tekin V, Saini S, Houson HA, Jayawardana SB, Decato DA, Wijeratne GB, and Lapi SE
- Subjects
- Mice, Animals, Tissue Distribution, Radiopharmaceuticals chemistry, Chelating Agents chemistry, Manganese, Positron-Emission Tomography methods, Radioisotopes
- Abstract
Introduction: Due to its decay and chemical properties, interest in manganese-52 has increased for development of long-lived PET radiopharmaceuticals. Its long half-life of 5.6 days, low average positron energy (242 keV), and sufficient positron decay branching ratio make it suitable for radiolabeling macromolecules for investigating slow biological processes. This work aims to establish suitable chelators for manganese-52 that can be radiolabeled at mild conditions through the evaluation of commercially available chelators., Methods: Manganese-52 was produced through the nuclear reaction
Nat Cr(p,n)52 Mn by irradiation of natural chromium targets on a TR24 cyclotron followed by purification through ion exchange chromatography. The radiolabeling efficiencies of chelators: DOTA, DiAmsar, TETA, DO3A, NOTA, 4'-Formylbenzo-15-crown-5, Oxo-DO3A, and DFO, were assessed by investigating the impact of pH, buffer type, and temperature. In vitro stability of [52 Mn]Mn(DO3A)- , [52 Mn]Mn(Oxo-DO3A)- , and [52 Mn]Mn(DOTA)2- were evaluated in mouse serum. The radiocomplexes were also evaluated in vivo in mice. Crystals of [Mn(Oxo-DO3A)]- were synthesized by reacting Oxo-DO3A with MnCl2 and characterized by single crystal X-ray diffraction., Results: Yields of 185 ± 19 MBq (5.0 ± 0.5 mCi) (n = 4) of manganese-52 were produced at the end of a 4 h, 15 μA, bombardment with 12.5 MeV protons. NOTA, DO3A, DOTA, and Oxo-DO3A chelators were readily radiolabeled with >96 % radiochemical purity at all conditions. Manganese radiocomplexes of Oxo-DO3A, DOTA, and DO3A remained stable in vitro up to 5 days and exhibited different biodistribution profiles compared to [52 Mn]MnCl2 . The solid-state structure of Mn-Oxo-DO3A complex was determined by single-crystal X-ray diffraction., Conclusions: DO3A and Oxo-DO3A are suitable chelators for manganese-52 which are readily radiolabeled at mild conditions with high molar activity, and demonstrate both in vitro and in vivo stability., Competing Interests: Declaration of competing interest The authors declare no known competing interests., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
19. [ 89 Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models.
- Author
-
Gallegos CA, Lu Y, Clements JC, Song PN, Lynch SE, Mascioni A, Jia F, Hartman YE, Massicano AVF, Houson HA, Lapi SE, Warram JM, Markert JM, and Sorace AG
- Subjects
- Animals, Mice, Humans, Tomography, X-Ray Computed, Immunotherapy, Positron-Emission Tomography, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Glioblastoma diagnostic imaging, Glioblastoma therapy
- Abstract
Rationale: Novel immune-activating therapeutics for the treatment of glioblastoma multiforme (GBM) have shown potential for tumor regression and increased survival over standard therapies. However, immunotherapy efficacy remains inconsistent with response assessment being complicated by early treatment-induced apparent radiological tumor progression and slow downstream effects. This inability to determine early immunotherapeutic benefit results in a drastically decreased window for alternative, and potentially more effective, treatment options. The objective of this study is to evaluate the effects of combination immunotherapy on early CD8
+ cell infiltration and its association with long term response in orthotopic syngeneic glioblastoma models. Methods: Luciferase positive GBM orthotopic mouse models (GSC005-luc) were imaged via [89 Zr]-CD8 positron emission tomography (PET) one week following treatment with saline, anti-PD1, M002 oncolytic herpes simplex virus (oHSV) or combination immunotherapy. Subsequently, brains were excised, imaged via [89 Zr]-CD8 ImmunoPET and evaluated though autoradiography and histology for H&E and CD8 immunohistochemistry. Longitudinal immunotherapeutic effects were evaluated through [89 Zr]-CD8 PET imaging one- and three-weeks following treatment, with changes in tumor volume monitored on a three-day basis via bioluminescence imaging (BLI). Response classification was then performed based on long-term BLI signal changes. Statistical analysis was performed between groups using one-way ANOVA and two-sided unpaired T-test, with p < 0.05 considered significant. Correlations between imaging and biological validation were assessed via Pearson's correlation test. Results: [89 Zr]-CD8 PET standardized uptake value (SUV) quantification was correlated with ex vivo SUV quantification (r = 0.61, p < 0.01), autoradiography (r = 0.46, p < 0.01), and IHC tumor CD8+ cell density (r = 0.55, p < 0.01). Classification of therapeutic responders, via bioluminescence signal, revealed a more homogeneous CD8+ immune cell distribution in responders (p < 0.05) one-week following immunotherapy. Conclusions: Assessment of early CD8+ cell infiltration and distribution in the tumor microenvironment provides potential imaging metrics for the characterization of oHSV and checkpoint blockade immunotherapy response in GBM. The combination therapies showed enhanced efficacy compared to single agent immunotherapies. Further development of immune-focused imaging methods can provide clinically relevant metrics associated with immune cell localization that can inform immunotherapeutic efficacy and subsequent treatment response in GBM patients., Competing Interests: Competing Interests: James M. Markert has the following relationships which may pose or be perceived as posing a financial conflict of interest. He is a board and equity holding member, in Aettis, Inc. and may receive royalties. The company holds frozen oncolytic viral stocks. Mustang Bio Tech is licensing the IP of C134 an oncolytic viral therapy. Markert is blinded to the conditions for the C134 clinical trials. He is a shareholder for this privately held Small Business Innovation Research LLC, Treovir, Inc., concerning G207 oncolytic viral therapy now in clinical trial. Merck, Inc. provides industry grant support by providing Keytruda (pembrolizumab) for a clinical trial of M032 oncolytic virotherapy now in clinical trial. Markert is a listee on Intellectual Property, related to a cancer immunotherapy system filed by in8Bio, formerly Incysus, Ltd. This IP has royalty earning potential., (© The author(s).)- Published
- 2024
- Full Text
- View/download PDF
20. Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.
- Author
-
Gimblet GR, Whitt J, Houson HA, Lin D, Guenter R, Rao TC, Wang D, Ness J, Gonzalez ML, Murphy MS, Gillis A, Chen H, Copland JA, Kenderian SS, Lloyd RV, Szkudlinski MW, Lapi SE, and Jaskula-Sztul R
- Subjects
- Animals, Humans, Male, Mice, Cell Line, Tumor, Iodine Radioisotopes, Mice, Nude, Positron-Emission Tomography methods, Thyrotropin, Tissue Distribution, Iodine, Receptors, Thyrotropin metabolism, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms pathology, Adenoma, Oxyphilic diagnostic imaging, Adenoma, Oxyphilic pathology
- Abstract
Background: Of the half a million cases of thyroid cancer diagnosed annually, 95% are differentiated thyroid cancers. Although clinical guidelines recommend surgical resection followed by radioactive iodine ablation, loss of sodium-iodine symporter expression causes up to 20% of differentiated thyroid cancers to become radioactive iodine refractory. For patients with radioactive iodine refractory disease, there is an urgent need for new diagnostic and therapeutic approaches. We evaluated the thyroid-stimulating hormone receptor as a potential target for imaging of differentiated thyroid cancer., Methods: We immunostained tissue microarrays containing 52 Hurthle cell carcinomas to confirm thyroid-stimulating hormone receptor expression. We radiolabeled chelator deferoxamine conjugated to recombinant human thyroid-stimulating hormone analog superagonist TR1402 with
89 Zr (t1/2 = 78.4 h, β+ =22.7%) to produce [89 Zr]Zr-TR1402. We performed in vitro uptake assays in high-thyroid-stimulating hormone receptor and low-thyroid-stimulating hormone receptor-expressing THJ529T and FTC133 thyroid cancer cell lines. We performed in vivo positron emission tomography/computed tomography and biodistribution studies in male athymic nude mice bearing thyroid-stimulating hormone receptor-positive THJ529T tumors., Results: Immunohistochemical analysis revealed 62% of patients (27 primary and 5 recurrent) were thyroid-stimulating hormone receptor membranous immunostain positive. In vitro uptake of 1nM [89 Zr]Zr-TR1402 was 38 ± 17% bound/mg in thyroid-stimulating hormone receptor-positive THJ529T thyroid cancer cell lines compared to 3.2 ± 0.5 in the low-expressing cell line (P < .01), with a similar difference seen in FTC133 cell lines (P < .0001). In vivo and biodistribution studies showed uptake of [89 Zr]Zr-TR1402 in thyroid-stimulating hormone receptor-expressing tumors, with a mean percentage of injected dose/g of 1.9 ± 0.4 at 3 days post-injection., Conclusion: Our observation of thyroid-stimulating hormone receptor expression in tissue microarrays and [89 Zr]Zr-TR1402 accumulation in thyroid-stimulating hormone receptor-positive thyroid cancer cells and tumors suggests thyroid-stimulating hormone receptor is a promising target for imaging of differentiated thyroid cancer., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
21. Evaluation of a novel hexadentate 1,2-hydroxypyridinone-based acyclic chelate, HOPO-O 6 -C4, for 43 Sc/ 47 Sc, 68 Ga, and 45 Ti radiopharmaceuticals.
- Author
-
Carbo-Bague I, Saini S, Cingoranelli SJ, Davey PRWJ, Tosato M, Lapi SE, and Ramogida CF
- Subjects
- Tissue Distribution, Titanium, Positron-Emission Tomography, Chelating Agents chemistry, Radiopharmaceuticals chemistry, Gallium Radioisotopes chemistry, Pyridones
- Abstract
Introduction: Chelators play a crucial role in the development of metal-based radiopharmaceuticals, and with the continued interest in
68 Ga and increasing availability of new radiometals such as43 Sc/47 Sc and45 Ti, there is a growing demand for tailored chelators that can form stable complexes with these metals. This work reports the synthesis and characterization of a hexadentate tris-1,2-hydroxypyridonone chelator HOPO-O6 -C4 and its in vitro and in vivo evaluation with the above mentioned radiometals., Methods: To investigate the affinity of HOPO-O6 -C4, macroscopic studies were performed with Sc3+ , and Ga3+ followed by DFT structural optimization of the Sc3+ , Ga3+ and Ti4+ complexes. Further tracer studies with43 Sc (and47 Sc),45 Ti, and68 Ga were performed to determine the potential for positron emission tomography (PET) imaging with these complexes. In vitro stability studies followed by in vivo imaging and biodistribution studies were performed to understand the kinetic stability of the resultant radiometal-complexes of HOPO-O6 -C4., Results: Promising radiolabeling results with HOPO-O6 -C4 were obtained with43 Sc,47 Sc,45 Ti, and68 Ga radionuclides; rapid radiolabeling was observed at 37 °C and pH 7 in under 30-min. Apparent molar activity measurements were performed for radiolabeling of HOPO-O6 -C4 with43 Sc (4.9 ± 0.26 GBq/μmol),47 Sc (1.58 ± 0.01 GBq/μmol),45 Ti (11.5 ± 1.6 GBq/μmol) and68 Ga (5.74 ± 0.7 GBq/μmol), respectively. Preclinical in vivo imaging studies resulted in promising results with [68 Ga]Ga-HOPO-O6 -C4 indicating a rapid clearance through hepatic excretion route and no decomplexation whereas [43 Sc]Sc-HOPO-O6 -C4, [47 Sc]Sc-HOPO-O6 -C4 and [45 Ti]Ti-HOPO-O6 -C4 showed modest and significant evidence of decomplexation, respectively., Conclusions: The tris-1,2-HOPO chelator HOPO-O6 -C4 is a promising scaffold for elaboration into a68 Ga- based radiopharmaceutical., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF
22. Production and purification of 43 Sc and 47 Sc from enriched [ 46 Ti]TiO 2 and [ 50 Ti]TiO 2 targets.
- Author
-
Cingoranelli SJ, Bartels JL, Kankanamalage PHA, Loveless CS, Rotsch DA, and Lapi SE
- Abstract
The radioscandium isotopes,
43 Sc and47 Sc, compose a promising elementally matched theranostic pair that can be used for the development of imaging and therapeutic radiopharmaceuticals with identical structures. This study aimed to investigate the production of high radionuclidic purity43 Sc from enriched [46 Ti]TiO2 targets and47 Sc from enriched [50 Ti]TiO2 targets and establish a target recycling technique. Enriched [46 Ti]TiO2 targets were irradiated with 18 MeV protons, and enriched [50 Ti]TiO2 targets were bombarded with 24 MeV protons.43 Sc and47 Sc were purified using ion chromatography attaining recovery yields of 91.7 ± 7.4% and 89.9 ± 3.9%, respectively. The average radionuclidic purity for43 Sc was 98.8 ± 0.3% and for47 Sc 91.5 ± 0.6%, while the average recovery of enriched titanium target material was 96 ± 4.0%. The highest apparent molar activity for [43 Sc]Sc-DOTA was 23.2 GBq/µmol and 3.39 GBq/µmol for [47 Sc]Sc-DOTA. This work demonstrates the feasibility of using enriched recycled [46 Ti]TiO2 and [50 Ti]TiO2 targets to produce high purity43 Sc and47 Sc as an elementally matched theranostic isotope pair., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
23. Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.
- Author
-
Phipps MD, Cingoranelli S, Bhupathiraju NVSDK, Younes A, Cao M, Sanders VA, Neary MC, Devany MH, Cutler CS, Lopez GE, Saini S, Parker CC, Fernandez SR, Lewis JS, Lapi SE, Francesconi LC, and Deri MA
- Subjects
- Animals, Mice, Chelating Agents chemistry, Positron-Emission Tomography methods, Ligands, Radiopharmaceuticals chemistry, Pyridones chemistry
- Abstract
Three isotopes of scandium─
43 Sc,44 Sc, and47 Sc─have attracted increasing attention as potential candidates for use in imaging and therapy, respectively, as well as for possible theranostic use as an elementally matched pair. Here, we present the octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO), an effective chelator for hard cations, as a potential ligand for use in radioscandium constructs with simple radiolabeling under mild conditions. HOPO forms a 1:1 Sc-HOPO complex that was fully characterized, both experimentally and theoretically. [47 Sc]Sc-HOPO exhibited good stability in chemical and biological challenges over 7 days. In healthy mice, [43,47 Sc]Sc-HOPO cleared the body rapidly with no signs of demetalation. HOPO is a strong candidate for use in radioscandium-based radiopharmaceuticals.- Published
- 2023
- Full Text
- View/download PDF
24. Construction of the Bioconjugate Py-Macrodipa-PSMA and Its In Vivo Investigations with Large 132/135 La 3+ and Small 47 Sc 3+ Radiometal Ions.
- Author
-
Hu A, Martin KE, Śmiłowicz D, Aluicio-Sarduy E, Cingoranelli SJ, Lapi SE, Engle JW, Boros E, and Wilson JJ
- Abstract
To harness radiometals in clinical settings, a chelator forming a stable complex with the metal of interest and targets the desired pathological site is needed. Toward this goal, we previously reported a unique set of chelators that can stably bind to both large and small metal ions, via a conformational switch. Within this chelator class, py-macrodipa is particularly promising based on its ability to stably bind several medicinally valuable radiometals including large
132/135 La3+ ,213 Bi3+ , and small44 Sc3+ . Here, we report a 10-step organic synthesis of its bifunctional analogue py-macrodipa-NCS, which contains an amine-reactive -NCS group that is amenable for bioconjugation reactions to targeting vectors. The hydrolytic stability of py-macordipa-NCS was assessed, revealing a half-life of 6.0 d in pH 9.0 aqueous buffer. This bifunctional chelator was then conjugated to a prostate-specific membrane antigen (PSMA)-binding moiety, yielding the bioconjugate py-macrodipa-PSMA, which was subsequently radiolabeled with large132/135 La3+ and small47 Sc3+ , revealing efficient and quantitative complex formation. The resulting radiocomplexes were injected into mice bearing both PSMA-expressing and PSMA-non-expressing tumor xenografts to determine their biodistribution patterns, revealing delivery of both132/135 La3+ and47 Sc3+ to PSMA+ tumor sites. However, partial radiometal dissociation was observed, suggesting that py-macrodipa-PSMA needs further structural optimization., Competing Interests: Conflict of Interest J.J.W. holds equity in Ratio Therapeutics (Boston, MA), which has licensed parts of this technology.- Published
- 2023
- Full Text
- View/download PDF
25. Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023).
- Author
-
Jalilian A, Decristoforo C, Denecke M, Elsinga PH, Hoehr C, Korde A, Lapi SE, and Scott PJH
- Abstract
The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA Headquarters in Vienna, Austria, during the week of 16-21 April 2023. This procedural paper summarizes highlights from symposium presentations, posters, panel discussions and satellite meetings, and provides additional resources that may be useful to researchers working with diagnostic and therapeutic radiopharmaceuticals in the academic, government and industry setting amongst IAEA Member States and beyond. More than 550 participants in person from 88 Member States attended the ISTR-2023. Over 360 abstracts were presented from all over the world by a diverse group of global scientists working with radiopharmaceuticals. Given this group of international radiochemists is unique to ISTR (IAEA funding enabled many to attend), there was an invaluable wealth of knowledge on the global state of the radiopharmaceutical sciences present at the meeting. The intent of this Proceedings paper is to share this snapshot from our international colleagues with the broader radiopharmaceutical sciences community by highlighting presentations from the conference on the following topics: Isotope Production and Radiochemistry, Industrial Insights, Regional Trends, Training and Education, Women in the Radiopharmaceutical Sciences, and Future Perspectives and New Initiatives. The authors of this paper are employees of IAEA, members of the ISTR-2023 Organizing Committee and/or members of the EJNMMI Radiopharmacy and Chemistry Editorial Board who attended ISTR-2023. Overall, ISTR-2023 fostered the successful exchange of scientific ideas around every aspect of the radiopharmaceutical sciences. It was well attended by a diverse mix of radiopharmaceutical scientists from all over the world, and the oral and poster presentations provided a valuable update on the current state-of-the-art of the field amongst IAEA Member States. Presentations as well as networking amongst the attendees resulted in extensive knowledge transfer amongst the various stakeholders representing 88 IAEA Member States. This was considered particularly valuable for attendees from Member States where nuclear medicine and the radiopharmaceutical sciences are still relatively new. Since the goal is for the symposium series to be held every four years; the next one is anticipated to take place in 2027., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
26. Optimized Methods for the Production of High-Purity 203 Pb Using Electroplated Thallium Targets.
- Author
-
Saini S, Bartels JL, Appiah JK, Rider JH, Baumhover N, Schultz MK, and Lapi SE
- Subjects
- Isotope Labeling, Radiopharmaceuticals, Chelating Agents chemistry, Thallium, Lead
- Abstract
203 Pb is a surrogate imaging match for212 Pb. This elementally matched pair is emerging as a suitable pair for imaging and targeted radionuclide therapy in cancer care. Because of the half-life (51.9 h) and low-energy γ-rays emitted,203 Pb is suitable for the development of diagnostic radiopharmaceuticals. The aim of this work was to optimize the production and separation of high-specific-activity203 Pb using electroplated thallium targets. We further investigated the radiochemistry optimization using a suitable chelator, tetraazacyclododecane-1,4,7-triacetic acid (DO3A), and targeting vector, VMT-α-NET (lead-specific chelator conjugated to tyr3-octreotide via a polyethylene glycol linker). Methods: Targets were prepared by electroplating of natural or enriched (205 Tl) thallium metal. Scanning electron microscopy was performed to determine the structure and elemental composition of electroplated targets. Targets were irradiated with 24-MeV protons with varying current and beam time to investigate target durability.203 Pb was purified from the thallium target material using an extraction resin (lead resin) column followed by a second column using a weak cation-exchange resin to elute the lead isotope as [203 Pb]PbCl2 Inductively coupled plasma mass spectrometry studies were used to further characterize the separation for trace metal contaminants. Radiolabeling efficiency was also investigated for DO3A chelator and VMT-α-NET (a peptide-based targeting conjugate). Results: Electroplated targets were prepared at a high plating density of 76-114 mg/cm2 using a plating time of 5 h. A reproducible separation method was established with a final elution in HCl (400 μL, 1 M) suitable for radiolabeling. Greater than 90% recovery yields were achieved, with an average specific activity of 37.7 ± 5.4 GBq/μmol (1.1 ± 0.1 Ci/μmol). Conclusion: An efficient electroplating method was developed to prepare thallium targets suitable for cyclotron irradiation. A simple and fast separation method was developed for routine203 Pb production with high recovery yields and purity., (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2023
- Full Text
- View/download PDF
27. Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities.
- Author
-
Ducharme M, Mansur A, Sligh L, Ulaner GA, Lapi SE, and Sorace AG
- Subjects
- Female, Humans, Receptor, ErbB-2, Receptor, ErbB-3, Breast Neoplasms diagnostic imaging, Breast Neoplasms metabolism, Positron-Emission Tomography methods
- Abstract
Human epidermal growth factor receptor 2 (HER2) and HER3 provide actionable targets for both therapy and imaging in breast cancer. Further, clinical trials have shown the prognostic impact of receptor status discordance in breast cancer. Intra- and intertumoral heterogeneity of both HER and hormone receptor expression contributes to inherent errors in tissue sampling, and single biopsies are incapable of identifying discordance in biomarker expression. Numerous PET radiopharmaceuticals have been developed to evaluate (or target for therapy) HER2 and HER3 expression. This review seeks to inform on challenges and opportunities in HER2 and HER3 PET imaging in both clinical and preclinical settings., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. In vivo Assessment of the Impact of Molecular Weight on Constructs of 68 Ga-DOTA-Manocept in a Syngeneic Mouse Tumor Model.
- Author
-
Bartels JL, Fernandez SR, Arnold JS, Parker CC, Tekin V, O'Malley G, Ralph DA, and Lapi SE
- Subjects
- Mice, Animals, Molecular Weight, Tissue Distribution, Cell Line, Tumor, Gallium Radioisotopes chemistry, Positron-Emission Tomography methods
- Abstract
Purpose: Manocept™ constructs are mannosylated amine dextrans (MADs) that bind with high affinity to the mannose receptor, CD206. Tumor-associated macrophages (TAMs) are the most numerous immune cells in the tumor microenvironment and a recognized target for tumor imaging and cancer immunotherapies. Most TAMs express CD206, suggesting utility of MADs to deliver imaging moieties or therapeutics to TAMs. The liver Kupffer cells also express CD206, making them an off-target localization site when targeting CD206 on TAMs. We evaluated TAM targeting strategies using two novel MADs differing in molecular weight in a syngeneic mouse tumor model to determine how varying MAD molecular weights would impact tumor localization. Increased mass dose of the non-labeled construct or a higher molecular weight (HMW) construct were also used to block liver localization and enhance tumor to liver ratios., Procedures: Two MADs, 8.7 kDa and 22.6 kDa modified with DOTA chelators, were synthesized and radiolabeled with
68 Ga. A HMW MAD (300 kDa) was also synthesized as a competitive blocking agent for Kupffer cell localization. Balb/c mice, with and without CT26 tumors, underwent dynamic PET imaging for 90 min followed by biodistribution analyses in selected tissues., Results: The new constructs were readily synthesized and labeled with68 Ga with ≥ 95% radiochemical purity in 15 min at 65 °C. When injected at doses of 0.57 nmol, the 8.7 kDa MAD provided 7-fold higher68 Ga tumor uptake compared to the 22.6 kDa MAD (2.87 ± 0.73%ID/g vs. 0.41 ± 0.02%ID/g). Studies with increased mass of unlabeled competitors showed reduced liver localization of the [68 Ga]MAD-8.7 to varying degrees without significant reductions in tumor localization, resulting in enhanced tumor to liver signal ratios., Conclusion: Novel [68 Ga]Manocept constructs were synthesized and studied in in vivo applications, showing that the smaller MAD localized to CT26 tumors more effectively than the larger MAD and that the unlabeled HMW construct could selectively block liver binding of [68 Ga]MAD-8.7 without diminishing the localization to tumors. Promising results using the [68 Ga]MAD-8.7 show a potential path to clinical applications., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
29. Evidence of neuroinflammation in fibromyalgia syndrome: a [ 18 F]DPA-714 positron emission tomography study.
- Author
-
Mueller C, Fang YD, Jones C, McConathy JE, Raman F, Lapi SE, and Younger JW
- Subjects
- Humans, Female, Neuroinflammatory Diseases, Quality of Life, Positron-Emission Tomography methods, Brain diagnostic imaging, Brain metabolism, Receptors, GABA metabolism, Fibromyalgia complications, Fibromyalgia diagnostic imaging, Fibromyalgia metabolism
- Abstract
Abstract: This observational study aimed to determine whether individuals with fibromyalgia (FM) exhibit higher levels of neuroinflammation than healthy controls (HCs), as measured with positron emission tomography using [ 18 F]DPA-714, a second-generation radioligand for the translocator protein (TSPO). Fifteen women with FM and 10 HCs underwent neuroimaging. Distribution volume (V T ) was calculated for in 28 regions of interest (ROIs) using Logan graphical analysis and compared between groups using multiple linear regressions. Group (FM vs HC) was the main predictor of interest and TSPO binding status (high- vs mixed-affinity) was added as a covariate. The FM group had higher V T in the right postcentral gyrus ( b = 0.477, P = 0.033), right occipital gray matter (GM; b = 0.438, P = 0.039), and the right temporal GM ( b = 0.466, P = 0.042). The FM group also had lower V T than HCs in the left isthmus of the cingulate gyrus ( b = -0.553, P = 0.014). In the subgroup of high-affinity binders, the FM group had higher V T in the bilateral precuneus, postcentral gyrus, parietal GM, occipital GM, and supramarginal gyrus. Group differences in the right parietal GM were associated with decreased quality of life, higher pain severity and interference, and cognitive problems. In support of our hypothesis, we found increased radioligand binding (V T ) in the FM group compared with HCs in several brain regions regardless of participants' TSPO binding status. The ROIs overlapped with prior reports of increased TSPO binding in FM. Overall, increasing evidence supports the hypothesis that FM involves microglia-mediated neuroinflammation in the brain., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.)
- Published
- 2023
- Full Text
- View/download PDF
30. Evaluation of [ 89 Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer.
- Author
-
Ducharme M, Hall L, Eckenroad W, Cingoranelli SJ, Houson HA, Jaskowski L, Hunter C, Larimer BM, and Lapi SE
- Subjects
- Humans, Female, Tissue Distribution, Trastuzumab metabolism, Positron-Emission Tomography, Receptor, ErbB-2 metabolism, Cell Line, Tumor, Zirconium chemistry, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Single-Domain Antibodies metabolism, Antineoplastic Agents
- Abstract
One of the most aggressive forms of breast cancer involves the overexpression of human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in ∼25% of all breast cancers and is associated with increased proliferation, increased rates of metastasis, and poor prognosis. Treatment for HER2-positive breast cancer has vastly improved since the development of the monoclonal antibody trastuzumab (Herceptin) as well as other biological constructs. However, patients still commonly develop resistance, illustrating the need for newer therapies. Nanobodies have become an important focus for potential development as HER2-targeting imaging agents and therapeutics. Nanobodies have many favorable characteristics, including high stability in heat and nonphysiological pH, while maintaining their low-nanomolar affinity for their designed targets. Specifically, the 2Rs15d nanobody has been developed for targeting HER2 and has been evaluated as a diagnostic imaging agent for single-photon emission computed tomography (SPECT) and positron emission tomography (PET). While a construct of 2Rs15d with the positron emitter
68 Ga is currently in phase I clinical trials, the only PET images acquired in preclinical or clinical research have been within 3 h postinjection. We evaluated our in-house produced 2Rs15d nanobody, conjugated with the chelator deferoxamine (DFO), and radiolabeled with89 Zr for PET imaging up to 72 h postinjection. [89 Zr]Zr-DFO-2Rs15d demonstrated high stability in both phosphate-buffered saline (PBS) and human serum. Cell binding studies showed high binding and specificity for HER2, as well as prominent internalization. Our in vivo PET imaging confirmed high-quality visualization of HER2-positive tumors up to 72 h postinjection, whereas HER2-negative tumors were not visualized. Subsequent biodistribution studies quantitatively supported the significant HER2-positive tumor uptake compared to the negative control. Our studies fill an important gap in understanding the imaging and binding properties of the 2Rs15d nanobody at extended time points. As many therapeutic radioisotopes have single or multiday half-lives, this information will directly benefit the potential of the radiotherapy development of 2Rs15d for HER2-positive breast cancer patients.- Published
- 2023
- Full Text
- View/download PDF
31. [ 89 Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models.
- Author
-
Massicano AVF, Song PN, Mansur A, White SL, Sorace AG, and Lapi SE
- Abstract
Triple-negative breast cancers (TNBCs) currently have limited treatment options; however, PD-L1 is an indicator of susceptibility to immunotherapy. Currently, assessment of PD-L1 is limited to biopsy samples. These limitations may be overcome with molecular imaging. In this work, we describe chemistry development and optimization, in vitro, in vivo, and dosimetry of [
89 Zr]-Atezolizumab for PD-L1 imaging. Atezolizumab was conjugated to DFO and radiolabeled with89 Zr. Tumor uptake and heterogeneity in TNBC xenograft and patient-derived xenograft (PDX) mouse models were quantified following [89 Zr]-Atezolizumab-PET imaging. PD-L1 expression in TNBC PDX models undergoing therapy and immunohistochemistry (IHC) was used to validate imaging. SUV from PET imaging was quantified and used to identify heterogeneity. PET/CT imaging using [89 Zr]-Atezolizumab identified a significant increase in tumor:muscle SUVmean 1 and 4 days after niraparib therapy and revealed an increased trend in PD-L1 expression following other cytotoxic therapies. A preliminary dosimetry study indicated the organs that will receive a higher dose are the spleen, adrenals, kidneys, and liver. [89 Zr]-Atezolizumab PET/CT imaging reveals potential for the noninvasive detection of PD-L1-positive TNBC tumors and allows for quantitative and longitudinal assessment. This has potential significance for understanding tumor heterogeneity and monitoring early expression changes in PD-L1 induced by therapy.- Published
- 2023
- Full Text
- View/download PDF
32. Impaired PPARγ activation by cadmium exacerbates infection-induced lung injury.
- Author
-
Larson-Casey JL, Liu S, Pyles JM, Lapi SE, Saleem K, Antony VB, Gonzalez ML, Crossman DK, and Carter AB
- Subjects
- Mice, Animals, Lung metabolism, Cadmium toxicity, Cadmium metabolism, Macrophages, Alveolar metabolism, PPAR gamma metabolism, Lung Injury chemically induced, Lung Injury metabolism
- Abstract
Emerging data indicate an association between environmental heavy metal exposure and lung disease, including lower respiratory tract infections (LRTIs). Here, we show by single-cell RNA sequencing an increase in Pparg gene expression in lung macrophages from mice exposed to cadmium and/or infected with Streptococcus pneumoniae. However, the heavy metal cadmium or infection mediated an inhibitory posttranslational modification of peroxisome proliferator-activated receptor γ (PPARγ) to exacerbate LRTIs. Cadmium and infection increased ERK activation to regulate PPARγ degradation in monocyte-derived macrophages. Mice harboring a conditional deletion of Pparg in monocyte-derived macrophages had more severe S. pneumoniae infection after cadmium exposure, showed greater lung injury, and had increased mortality. Inhibition of ERK activation with BVD-523 protected mice from lung injury after cadmium exposure or infection. Moreover, individuals residing in areas of high air cadmium levels had increased cadmium concentration in their bronchoalveolar lavage (BAL) fluid, increased barrier dysfunction, and showed PPARγ inhibition that was mediated, at least in part, by ERK activation in isolated BAL cells. These observations suggest that impaired activation of PPARγ in monocyte-derived macrophages exacerbates lung injury and the severity of LRTIs.
- Published
- 2023
- Full Text
- View/download PDF
33. Evaluation of a CD206-Targeted Peptide for PET Imaging of Macrophages in Syngeneic Mouse Models of Cancer.
- Author
-
Parker CC, Bin Salam A, Song PN, Gallegos C, Hunt A, Yates C, Jaynes J, Lopez H, Massicano AVF, Sorace AG, Fernandez S, Houson HA, and Lapi SE
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Macrophages metabolism, Peptides metabolism, Positron-Emission Tomography methods, Tissue Distribution, Mannose Receptor metabolism, Gallium Radioisotopes chemistry, Neoplasms metabolism
- Abstract
Tumor-associated macrophages (TAMs) are large phagocytic cells that play numerous roles in cancer biology and are an important component of the relationship between immune system response and tumor progression. The peptide, RP832c, targets the Mannose Receptor (CD206) expressed on M2-like macrophages and is cross-reactive to both human and murine CD206. Additionally, it exhibits therapeutic properties through its ability to shift the population of TAMs from an M2-like (protumor) toward an M1-like phenotype (antitumor) and has demonstrated promise in inhibiting tumor resistance in PD-L1 unresponsive melanoma murine models. In addition, it has shown inhibition in bleomycin-induced pulmonary fibrosis through interactions with CD206 macrophages.
1,2 Our work aims to develop a novel CD206 positron emission tomography (PET) imaging probe based on RP832c ( Kd = 5.64 μM) as a direct, noninvasive method for the assessment of TAMs in mouse models of cancer. We adapted RP832c to incorporate the chelator DOTA to allow for radiolabeling with the PET isotope68 Ga ( t1/2 = 68 min; ß+ = 89%). In vitro stability studies were conducted in mouse serum up to 3 h. The in vitro binding characteristics of [68 Ga]RP832c to CD206 were determined by a protein plate binding assay and Surface Plasmon Resonance (SPR). PET imaging and biodistribution studies were conducted in syngeneic tumor models. Stability studies in mouse serum demonstrated that68 Ga remained complexed up to 3 h (less than 1% free68 Ga). Binding affinity studies demonstrated high binding of [68 Ga]RP832c to mouse CD206 protein and that the binding of the tracer was able to be blocked significantly when incubated with a blocking solution of native RP832c. PET imaging and biodistribution studies in syngeneic tumor models demonstrated uptake in tumor and CD206 expressing organs of [68 Ga]RP832c. A significant correlation was found between the percentage of CD206 present in each tumor imaged with [68 Ga]RP832c and PET imaging mean standardized uptake values in a CT26 mouse model of cancer. The data shows that [68 Ga]RP832c represents a promising candidate for macrophage imaging in cancer and other diseases.- Published
- 2023
- Full Text
- View/download PDF
34. Direct Radiolabeling of Trastuzumab-Targeting Triblock Copolymer Vesicles with 89 Zr for Positron Emission Tomography Imaging.
- Author
-
Kozlovskaya V, Ducharme M, Dolmat M, Omweri JM, Tekin V, Lapi SE, and Kharlampieva E
- Subjects
- Animals, Mice, Humans, Female, Trastuzumab, Tissue Distribution, Polymers therapeutic use, Chelating Agents, Zirconium, Cell Line, Tumor, Positron-Emission Tomography methods, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy, Breast Neoplasms pathology
- Abstract
Radiolabeled drug nanocarriers that can be easily imaged via positron emission tomography (PET) are highly significant as their in vivo outcome can be quantitatively PET-traced with high sensitivity. However, typical radiolabeling of most PET-guided theranostic vehicles utilizes modification with chelator ligands, which presents various challenges. In addition, unlike passive tumor targeting, specific targeting of drug delivery vehicles via binding affinity to overexpressed cancer cell receptors is crucial to improve the theranostic delivery to tumors. Herein, we developed
89 Zr-labeled triblock copolymer polymersomes of 60 nm size through chelator-free radiolabeling. The polymersomes are assembled from poly( N -vinylpyrrolidone)5 - b -poly(dimethylsiloxane)30 - b -poly( N -vinylpyrrolidone)5 (PVPON5 -PDMS30 -PVPON5 ) triblock copolymers followed by adsorption of a degradable tannin, tannic acid (TA), on the polymersome surface through hydrogen bonding. TA serves as an anchoring layer for both89 Zr radionuclide and targeting recombinant humanized monoclonal antibody, trastuzumab (Tmab). Unlike bare PVPON5 -PDMS30 -PVPON5 polymersomes, TA- and Tmab-modified polymersomes demonstrated a high radiochemical yield of more than 95%. Excellent retention of89 Zr by the vesicle membrane for up to 7 days was confirmed by PET in vivo imaging. Animal biodistribution using healthy BALB/c mice confirmed the clearance of89 Zr-labeled polymersomes through the spleen and liver without their accumulation in bone, unlike the free nonbound89 Zr radiotracer. The89 Zr-radiolabeled polymersomes were found to specifically target BT474 HER2-positive breast cancer cells via the Tmab-TA complex on the vesicle surface. The noncovalent Tmab anchoring to the polymersome membrane can be highly advantageous for nanoparticle modification compared to currently developed covalent methods, as it allows easy and quick integration of a broad range of targeting proteins. Given the ability of these polymersomes to encapsulate and release anticancer therapeutics, they can be further expanded as precision-targeted therapeutic carriers for advancing human health through highly effective drug delivery strategies.- Published
- 2023
- Full Text
- View/download PDF
35. Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.
- Author
-
Lin W, Aluicio-Sarduy E, Houson HA, Barnhart TE, Tekin V, Jeffery JJ, Weichmann AM, Barrett KE, Lapi SE, and Engle JW
- Subjects
- Female, Mice, Humans, Animals, Pilot Projects, Mice, Nude, Neurotensin therapeutic use, Neurotensin metabolism, Receptors, Neurotensin metabolism, Precision Medicine
- Abstract
Neurotensin receptor 1 (NTSR1) can stimulate tumor proliferation through neurotensin (NTS) activation and are overexpressed by a variety of cancers. The high binding affinity of NTS/NTSR1 makes radiolabeled NTS derivatives interesting for cancer diagnosis and staging. Internalization of NTS/NTSR1 also suggests therapeutic application with high LET alpha particles and low energy electrons. We investigated the therapeutic efficacy of [
58m Co]Co-NOTA-NT-20.3 in vivo using murine models xenografted with NTSR1-positive HT29 human colorectal adenocarcinoma cells, and utilized [55 Co]Co-NOTA-NT-20.3 for dosimetry., Methods: Targeting properties and cytotoxicity of [55/58m Co]Co-NOTA-NT-20.3 were assessed with HT29 cells. Female nude mice were xenografted with HT29 tumors and administered [55 Co or58m Co]Co-NOTA-NT-20.3 to evaluate pharmacokinetics or for therapy, respectively. Dosimetry calculations followed the Medical Internal Radiation Dose (MIRD) formalism and human absorbed dose rate per unit activity were obtained from OpenDose. The pilot therapy study consisted of two groups (each N = 3) receiving 110 ± 15 MBq and 26 ± 6 MBq [58m Co]Co-NOTA-NT-20.3 one week after tumor inoculation, and control (N = 3). Tumor sizes and masses were measured twice a week after therapy. Complete blood count and kidney histology were also performed to assess toxicity., Results: HPLC measured radiochemical purity of [55,58m Co]Co-NOTA-NT-20.3 > 99 %. Labeled compounds retained NTS targeting properties. [58m Co]Co-NOTA-NT-20.3 exhibited cytotoxicity for HT29 cells and was >15× more potent than [58m Co]CoCl2 . Xenografted tumors responded modestly to administered doses, but mice showed no signs of radiotoxicity. Absorbed dose to tumor and kidney with 110 MBq [58m Co]Co-NOTA-NT-20.3 were 0.6 Gy and 0.8 Gy, respectively, and other organs received less than half of the absorbed dose to tumor. Off-target radiation dose from cobalt-58g was small but reduces the therapeutic window., Conclusion: The enhanced in vitro cytotoxicity and high tumor-to-background led us to investigate the therapeutic efficacy of [58m Co]Co-NOTA-NT-20.3 in vivo. Although we were unable to induce tumor response commensurate with [177 Lu]Lu-NT127 (NLys-Lys-Pro-Tyr-Tle-Leu) studies involving similar time-integrated activity, the absence of observed toxicity may constitute an opportunity for targeting vectors with improved uptake and/or retention to avoid the aftereffects of other high-LET radioactive emissions. Future studies with higher uptake, activity and/or multiple dosing regimens are warranted. The theranostic approach employed in this work was crucial for dosimetry analysis., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
36. Natural and enriched Cr target development for production of Manganese-52.
- Author
-
Pyles JM, Omweri JM, and Lapi SE
- Subjects
- Oxides, Chromium, Manganese, Radioisotopes
- Abstract
52 Mn is a promising PET radiometal with a half-life of 5.6 days and an average positron energy of 242 keV. Typically, chromium of natural isotope abundance is used as a target material to produce this isotope through thenat/52 Cr(p,n)52 Mn reaction. While natural Cr is a suitable target material, higher purity52 Mn could be produced by transitioning to enriched52 Cr targets to prevent the co-production of long-lived54 Mn (t1/2 = 312 day). Unfortunately,52 Cr targets are not cost-effective without recycling processes in place, therefore, this work aims to explore routes to prepare Cr targets that could be recycled. Natural Cr foils, metal powder pellets, enriched chromium-52 oxide and Cr(III) electroplated targets were investigated in this work. Each of these cyclotron targets were irradiated, and the produced52 Mn was purified, when possible, using a semi-automated system. An improved purification by solid-phase anion exchange from ethanol-HCl mixtures resulted in recoveries of 94.5 ± 2.2% of52 Mn. The most promising target configuration to produce a recyclable target was electroplated Cr(III). This work presents several pathways to optimize enriched Cr targets for the production of high purity52 Mn., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
37. Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma.
- Author
-
Shin J, Parker MFL, Zhu I, Alanizi A, Rodriguez CI, Liu R, Watchmaker PB, Kalita M, Blecha J, Luu J, Wright B, Lapi SE, Flavell RR, Okada H, Tlsty TD, Roybal KT, and Wilson DM
- Subjects
- Animals, Humans, Female, T-Lymphocytes, Cell Line, Tumor, Positron-Emission Tomography methods, Genes, Reporter, Glioblastoma, Breast Neoplasms diagnostic imaging, Breast Neoplasms genetics
- Abstract
For the past several decades, chimeric antigen receptor T-cell therapies have shown promise in the treatment of cancers. These treatments would greatly benefit from companion imaging biomarkers to follow the trafficking of T cells in vivo. Methods: Using synthetic biology, we engineered T cells with a chimeric receptor synthetic intramembrane proteolysis receptor (SNIPR) that induces overexpression of an exogenous reporter gene cassette on recognition of specific tumor markers. We then applied a SNIPR-based PET reporter system to 2 cancer-relevant antigens, human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor variant III (EGFRvIII), commonly expressed in breast and glial tumors, respectively. Results: Antigen-specific reporter induction of the SNIPR PET T cells was confirmed in vitro using green fluorescent protein fluorescence, luciferase luminescence, and the HSV-TK PET reporter with 9-(4-
18 F-fluoro-3-[hydroxymethyl]butyl)guanine ([18 F]FHBG). T cells associated with their target antigens were successfully imaged using PET in dual-xenograft HER2+/HER2- and EGFRvIII+/EGFRvIII- animal models, with more than 10-fold higher [18 F]FHBG signals seen in antigen-expressing tumors versus the corresponding controls. Conclusion: The main innovation found in this work was PET detection of T cells via specific antigen-induced signals, in contrast to reporter systems relying on constitutive gene expression., (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2023
- Full Text
- View/download PDF
38. PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68.
- Author
-
Houson HA, Tekin V, Lin W, Aluicio-Sarduy E, Engle JW, and Lapi SE
- Abstract
Introduction: Neurotensin receptor 1 (NTSR1) is an emerging target for imaging and therapy of many types of cancer. Nuclear imaging of NTSR1 allows for noninvasive assessment of the receptor levels of NTSR1 on the primary tumor, as well as potential metastases. This work focuses on a the neurotensin peptide analogue NT-20.3 conjugated to the chelator NOTA for radiolabeling for use in noninvasive positron emission tomography (PET). NOTA-NT-20.3 was radiolabeled with gallium-68, copper-64, and cobalt-55 to determine the effect that modification of the radiometal has on imaging and potential therapeutic properties of NOTA-NT-20.3. Methods: In vitro assays investigating cell uptake and subcellular localization of the radiolabeled peptides were performed using human colorectal adenocarcinoma HT29 cells. In vivo PET/CT imaging was used to determine the distribution and clearance of the peptide in mice bearing NTSR1 expressing HT29 tumors. Results: Cell uptake studies showed that the highest uptake was obtained with [55Co] Co-NOTA-NT-20.3 (18.70 ± 1.30%ID/mg), followed by [64Cu] Cu-NOTA-NT-20.3 (15.46 ± 0.91%ID/mg), and lastly [68Ga] Ga-NOTA-NT-20.3 (10.94 ± 0.46%ID/mg) (p < 0.001). Subcellular distribution was similar across the three constructs, with the membranous fraction containing the highest amount of radioactivity. In vivo PET/CT imaging of the three constructs revealed similar distribution and tumor uptake at the 1 h imaging timepoint. Tumor uptake was receptor-specific and blockable by co-injection of non-radiolabeled NOTA-NT-20.3. SUV ratios of tumor to heart at the 24 h imaging timepoint show that [55Co] Co-NOTA-NT-20.3 (20.28 ± 3.04) outperformed [64Cu] Cu-NOTA-NT-20.3 (6.52 ± 1.97). In conclusion, our studies show that enhanced cell uptake and increasing tumor to blood ratios over time displayed the superiority of [55Co] Co-NOTA-NT-20.3 over [68Ga] Ga-NOTA-NT-20.3 and [64Cu] Cu-NOTA-NT-20.3 for the targeting of NTSR1.
- Published
- 2022
- Full Text
- View/download PDF
39. 89 Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model.
- Author
-
Stone LD, Massicano AVF, Stevens TM, Warram JM, Morlandt AB, Lapi SE, and Amm HM
- Subjects
- Animals, Humans, Mice, Panitumumab, Tissue Distribution, Positron Emission Tomography Computed Tomography, Zirconium, Cell Line, Tumor, Positron-Emission Tomography methods, Ameloblastoma diagnostic imaging, Ameloblastoma surgery
- Abstract
Accurate assessment of tumor margins with specific, non-invasive imaging would result in the preservation of healthy tissue and improve long-term local tumor control, thereby reducing the risk of recurrence. Overexpression of epidermal growth factor receptor (EGFR) has been used in other cancers as an imaging biomarker to identify cancerous tissue. We hypothesize that expression of EGFR in ameloblastomas may be used to specifically visualize tumors. The aims of this study are to measure the specificity of radiolabeled
89 Zr-panitumumab (an EGFR antibody) in vivo using patient-derived xenograft (PDX) models of ameloblastoma and positron emission tomography/computed tomography (PET/CT) scans. In PDX of ameloblastomas from four patients (AB-36, AB-37, AB-39 AB-53), the biodistribution of89 Zr-panitumumab was measured 120 h post-injection and was reported as the injected dose per gram of tissue (%ID/g; AB-36, 40%; AB-37, 62%; AB-39 18%; AB-53, 65%). The radiolabeled %ID/g was significantly greater in tumors of89 Zr-panitumumab-treated mice that did not receive unlabeled panitumumab as a blocking control for AB-36, AB-37, and AB-53. Radiolabeled anti-EGFR demonstrates specificity for ameloblastoma PDX tumor xenografts, we believe89 Zr-panitumumab is an attractive target for pre-surgical imaging of ameloblastomas. With this technology, we could more accurately assess tumor margins for the surgical removal of ameloblastomas., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
40. Evaluation of 68 Ga-Radiolabeled Peptides for HER2 PET Imaging.
- Author
-
Ducharme M, Houson HA, Fernandez SR, and Lapi SE
- Abstract
One in eight women will be diagnosed with breast cancer in their lifetime and approximately 25% of those cases will be HER2-positive. Current methods for diagnosing HER2-positive breast cancer involve using IHC and FISH from suspected cancer biopsies to quantify HER2 expression. HER2 PET imaging could potentially increase accuracy and improve the diagnosis of lesions that are not available for biopsies. Using two previously discovered HER2-targeting peptides, we modified each peptide with the chelator DOTA and a PEG2 linker resulting in DOTA-PEG2-GSGKCCYSL (P5) and DOTA-PEG2-DTFPYLGWWNPNEYRY (P6). Each peptide was labeled with 68Ga and was evaluated for HER2 binding using in vitro cell studies and in vivo tumor xenograft models. Both [68Ga]P5 and [68Ga]P6 showed significant binding to HER2-positive BT474 cells versus HER2-negative MDA-MB-231 cells ([68Ga]P5; 0.68 ± 0.20 versus 0.47 ± 0.05 p < 0.05 and [68Ga]P6; 0.55 ± 0.21 versus 0.34 ± 0.12 p < 0.01). [68Ga]P5 showed a higher percent injected dose per gram (%ID/g) binding to HER2-positive tumors two hours post-injection compared to HER2-negative tumors (0.24 ± 0.04 versus 0.12 ± 0.06; p < 0.05), while the [68Ga]P6 peptide showed significant binding (0.98 ± 0.22 versus 0.51 ± 0.08; p < 0.05) one hour post-injection. These results lay the groundwork for the use of peptides to image HER2-positive breast cancer.
- Published
- 2022
- Full Text
- View/download PDF
41. A General Design Strategy Enabling the Synthesis of Hydrolysis-Resistant, Water-Stable Titanium(IV) Complexes.
- Author
-
Koller AJ, Saini S, Chaple IF, Joaqui-Joaqui MA, Paterson BM, Ma MT, Blower PJ, Pierre VC, Robinson JR, Lapi SE, and Boros E
- Subjects
- Catalysis, Chelating Agents, Hydrolysis, Water chemistry, Organometallic Compounds chemistry, Titanium chemistry
- Abstract
Despite its prevalence in the environment, the chemistry of the Ti
4+ ion has long been relegated to organic solutions or hydrolyzed TiO2 polymorphs. A knowledge gap in stabilizing molecular Ti4+ species in aqueous environments has prevented the use of this ion for various applications such as radioimaging, design of water-compatible metal-organic frameworks (MOFs), and aqueous-phase catalysis applications. Herein, we show a thorough thermodynamic screening of bidentate chelators with Ti4+ in aqueous solution, as well as computational and structural analyses of key compounds. In addition, the hexadentate analogues of catechol (benzene-1,2-diol) and deferiprone (3-hydroxy-1,2-dimethyl-4(1H)-pyridone), TREN-CAM and THPMe respectively, were assessed for chelation of the45 Ti isotope (t1/2 =3.08 h, β+ =85 %, Eβ+ =439 keV) towards positron emission tomography (PET) imaging applications. Both were found to have excellent capacity for kit-formulation, and [45 Ti]Ti-TREN-CAM was found to have remarkable stability in vivo., (© 2022 Wiley-VCH GmbH.)- Published
- 2022
- Full Text
- View/download PDF
42. 45 Ti targeted tracers for PET imaging of PSMA.
- Author
-
Chaple IF, Houson HA, Koller A, Pandey A, Boros E, and Lapi SE
- Subjects
- Cell Line, Tumor, Humans, Male, Positron-Emission Tomography methods, Radiopharmaceuticals chemistry, Antigens, Surface metabolism, Glutamate Carboxypeptidase II metabolism, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms metabolism, Titanium
- Abstract
Purpose: Positron Emission Tomography is an important molecular imaging technique for detection and diagnoses of various disease states. This work aims to develop novel titanium-45 (t
½ = 3.08 h) PET tracers using Prostate Specific Membrane Antigen (PSMA) targeting vectors for imaging of prostate cancer as proof of concept for this relatively unexplored isotope., Procedures: Titanium-45 was produced on the University of Alabama at Birmingham (UAB) TR24 cyclotron using proton bombardments on natural scandium foils and separated using procedures described previously [1]. After purification, Titanium-45 was used to radiolabel two PSMA-targeting molecules; DFO-DUPA and LDFC-DUPA. Radiochemical yields were determined via radio-high purity liquid chromatography (radioHPLC). The radiolabeled compounds were tested both in vitro and in vivo using PSMA+ cell lines (LNCaP and 22Rv1) and PSMA- cell lines (PC3)., Results: Titanium-45 was produced and purified in yields suitable for research studies. Radiochemical yields of up to 98 ± 1% were achieved with DFO-DUPA and 92 ± 7% with LDFC-DUPA. PSMA specific targeting was observed in vitro in PSMA positive cells (LNCaP (0.6% ± 0.05%) and confirmed by blocking (0.15% ± 0.04%) (P < 0.0001)), compared to uptake in the PSMA negative cells (PC3 (0.07% ± 0.008%)) and confirmed by blocking (0.07% ± 0.01%) (P = 0.5253). In vivo studies demonstrated statistically significant uptake in LNCaP tumors (2.3% ± 0.3% ID/g) compared to PC3 tumor uptake (0.1% ± 0.07%)., Conclusions: This work shows that titanium-45 can be used to radiolabel PSMA targeting compounds with high radiochemical yields. These radiolabeled compounds remain intact in serum for at least two half-lives of titanium-45, showing that these compounds would be appropriate for implementation in the clinical setting. This study shows the feasibility of using titanium-45 as positron emitting radiometal for use in imaging PSMA+ prostate cancer, and illustrates that further research is in this area is warranted., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
43. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.
- Author
-
Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, Heinzman K, Lapi SE, Yang ES, and Sorace AG
- Abstract
DNA damage repair and tumor hypoxia contribute to intratumoral cellular and molecular heterogeneity and affect radiation response. The goal of this study is to investigate anti-HER2-induced radiosensitization of the tumor microenvironment to enhance fractionated radiotherapy in models of HER2+ breast cancer. This is monitored through in vitro and in vivo studies of phosphorylated γ-H2AX, [
18 F]-fluoromisonidazole (FMISO)-PET, and transcriptomic analysis. In vitro, HER2+ breast cancer cell lines were treated with trastuzumab prior to radiation and DNA double-strand breaks (DSB) were quantified. In vivo, HER2+ human cell line or patient-derived xenograft models were treated with trastuzumab, fractionated radiation, or a combination and monitored longitudinally with [18 F]-FMISO-PET. In vitro DSB analysis revealed that trastuzumab administered prior to fractionated radiation increased DSB. In vivo, trastuzumab prior to fractionated radiation significantly reduced hypoxia, as detected through decreased [18 F]-FMISO SUV, synergistically improving long-term tumor response. Significant changes in IL-2, IFN-gamma, and THBS-4 were observed in combination-treated tumors. Trastuzumab prior to fractionated radiation synergistically increases radiotherapy in vitro and in vivo in HER2+ breast cancer which is independent of anti-HER2 response alone. Modulation of the tumor microenvironment, through increased tumor oxygenation and decreased DNA damage response, can be translated to other cancers with first-line radiation therapy.- Published
- 2022
- Full Text
- View/download PDF
44. Meet the advisors - Suzy Lapi.
- Author
-
Lapi SE and Trevorrow P
- Published
- 2022
- Full Text
- View/download PDF
45. Evaluation of 177 Lu and 47 Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.
- Author
-
Vaughn BA, Loveless CS, Cingoranelli SJ, Schlyer D, Lapi SE, and Boros E
- Subjects
- Animals, Dipeptides pharmacokinetics, Heterocyclic Compounds, 1-Ring pharmacokinetics, Humans, Male, Mice, Prostate-Specific Antigen pharmacokinetics, Prostatic Neoplasms mortality, Radiopharmaceuticals pharmacokinetics, Tissue Distribution, Chelating Agents chemistry, Dipeptides therapeutic use, Heterocyclic Compounds, 1-Ring therapeutic use, Lutetium therapeutic use, Prostate-Specific Antigen therapeutic use, Prostatic Neoplasms radiotherapy, Radioisotopes therapeutic use, Radiopharmaceuticals therapeutic use, Scandium therapeutic use
- Abstract
Lu-177-based, targeted radiotherapeutics/endoradiotherapies are an emerging clinical tool for the management of various cancers. The chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) remains the workhorse for such applications but can limit apparent molar activity or efficient charge modulation, which can impact target binding and, as a consequence, target efficacy. Previously, our lab had developed the small, rare earth selective bifunctional chelator, picaga, as an efficient bifunctional chelator for scandium and lutetium isotopes. Here, we assess the performance of these constructs for therapy in prostate-specific membrane antigen (PSMA)-expressing tumor xenografts. To assess the viability of picaga conjugates in conjunction with long in vivo circulation, a picaga conjugate functionalized with a serum albumin binding moiety,
177 Lu-picaga-Alb53-PSMA, was also synthesized. A directly comparative, low, single 3.7 MBq dose treatment study with Lu-PSMA-617 was conducted. Treatment with177 Lu-picaga-Alb53-PSMA resulted in tumor regression and lengthened median survival (54 days) when compared with the vehicle (16 days),47 Sc-picaga-DUPA-,177 Lu-picaga-DUPA-, and177 Lu-PSMA-617-treated cohorts (21, 23, and 21 days, respectively).- Published
- 2021
- Full Text
- View/download PDF
46. A heavy-ion production channel of 149 Tb via 63 Cu bombardment of 89 Y.
- Author
-
Wilkinson JT, Barrett KE, Ferran SJ, McGuinness SR, McIntosh LA, McCarthy M, Yennello SJ, Engle JW, Lapi SE, and Peaslee GF
- Subjects
- Half-Life, Spectrometry, Gamma, Copper chemistry, Radioisotopes chemistry, Terbium chemistry, Yttrium Isotopes chemistry
- Abstract
The radionuclide
149 Tb (t1/2 = 4.1 h) is a potential theranostic isotope which can simultaneously be used for targeted-alpha-particle therapy and positron-emission tomography. Feasibility experiments were performed to test a near-symmetric heavy-ion reaction of63 Cu bombardment on monoisotopic89 Y. The indirect reaction was studied to avoid isomer production. Offline gamma spectroscopy was used to quantify thick-target physical yields and experimental results show modest agreement to the fusion-evaporation code PACE4. A near-symmetric fission yield was also observed., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
47. Author Correction: Positron emission tomography imaging with 89 Zr-labeled anti-CD8 cys-diabody reveals CD8 + cell infiltration during oncolytic virus therapy in a glioma murine model.
- Author
-
Kasten BB, Houson HA, Coleman JM, Leavenworth JW, Markert JM, Wu AM, Salazar F, Tavaré R, Massicano AVF, Gillespie GY, Lapi SE, Warram JM, and Sorace AG
- Published
- 2021
- Full Text
- View/download PDF
48. Novel Tracers and Radionuclides in PET Imaging.
- Author
-
Mason C, Gimblet GR, Lapi SE, and Lewis JS
- Subjects
- Humans, Cardiovascular Diseases diagnostic imaging, Neurodegenerative Diseases diagnostic imaging, Positron-Emission Tomography trends, Precision Medicine trends, Radiopharmaceuticals
- Abstract
The use of PET imaging agents in oncology, cardiovascular disease, and neurodegenerative disease shows the power of this technique in evaluating the molecular and biological characteristics of numerous diseases. These agents provide crucial information for designing therapeutic strategies for individual patients. Novel PET tracers are in continual development and many have potential use in clinical and research settings. This article discusses the potential applications of tracers in diagnostics, the biological characteristics of diseases, the ability to provide prognostic indicators, and using this information to guide treatment strategies including monitoring treatment efficacy in real time to improve outcomes and survival., Competing Interests: Disclosure With regard to the information presented in this article the authors have no potential conflicts of interest to disclose., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Production of 52 Mn using a semi-automated module.
- Author
-
Pyles JM, Massicano AVF, Appiah JP, Bartels JL, Alford A, and Lapi SE
- Abstract
This work focused on the production and purification of the positron emitter
52 Mn (t1/2 = 5.6 d) via thenat Cr(p,n)52 Mn reaction, using a TR24 cyclotron and a semi-automated system for the purification of52 Mn. Based on two-column and three-column systems, the recovery of52 Mn was 79.7 ± 6.2% (n = 3) and 70.8 ± 3.3% (n = 3), with processing times of 6.9 ± 0.5 h and 8.2 ± 0.6 h, respectively., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
50. Positron emission tomography imaging with 89 Zr-labeled anti-CD8 cys-diabody reveals CD8 + cell infiltration during oncolytic virus therapy in a glioma murine model.
- Author
-
Kasten BB, Houson HA, Coleman JM, Leavenworth JW, Markert JM, Wu AM, Salazar F, Tavaré R, Massicano AVF, Gillespie GY, Lapi SE, Warram JM, and Sorace AG
- Subjects
- Animals, CD8 Antigens antagonists & inhibitors, CD8 Antigens isolation & purification, CD8-Positive T-Lymphocytes virology, Cell Line, Tumor, Disease Models, Animal, Glioma diagnostic imaging, Glioma immunology, Glioma virology, Humans, Mice, Radioisotopes pharmacology, Simplexvirus genetics, Tomography, X-Ray Computed, Zirconium pharmacology, CD8 Antigens immunology, CD8-Positive T-Lymphocytes immunology, Glioma therapy, Oncolytic Virotherapy methods
- Abstract
Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a process which can take months. Detection of CD8
+ T cell recruitment to the tumor with a noninvasive imaging modality such as positron emission tomography (PET) may allow for tumor characterization and early evaluation of therapeutic response to immunotherapy. In this study, we utilized89 Zr-labeled anti-CD8 cys-diabody-PET to provide proof-of-concept to detect CD8+ T cell immune response to oncolytic herpes simplex virus (oHSV) M002 immunotherapy in a syngeneic GBM model. Immunocompetent mice (n = 16) were implanted intracranially with GSC005 GBM tumors, and treated with intratumoral injection of oHSV M002 or saline control. An additional non-tumor bearing cohort (n = 4) receiving oHSV M002 treatment was also evaluated. Mice were injected with89 Zr-labeled anti-CD8 cys-diabody seven days post oHSV administration and imaged with a preclinical PET scanner. Standardized uptake value (SUV) was quantified. Ex vivo tissue analyses included autoradiography and immunohistochemistry. PET imaging showed significantly higher SUV in tumors which had been treated with M002 compared to those without M002 treatment (p = 0.0207) and the non-tumor bearing M002 treated group (p = 0.0021). Accumulation in target areas, especially the spleen, was significantly reduced by blocking with the non-labeled diabody (p < 0.001). Radioactive probe accumulation in brains was consistent with CD8+ cell trafficking patterns after oHSV treatment. This PET imaging strategy could aid in distinguishing responders from non-responders during immunotherapy of GBM., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.